Why is pegaspargase preferred over native asparaginase?

Its long half-life means far fewer injections for equivalent asparagine depletion, and PEGylation reduces (though does not remove) allergic reactions, which is why it is standard first-line in many modern ALL protocols.

Is pegaspargase approved by regulators?

Yes. It is FDA-approved, including a first-line indication for childhood ALL, and is used within standard multi-agent ALL regimens.

What side effects should be watched for?

Allergic reactions, pancreatitis, blood clots (including in the brain), liver dysfunction, high blood sugar, and high triglycerides. Doctors also monitor asparaginase activity to detect silent loss of drug effect.

Can I obtain pegaspargase as a research peptide?

No. It is a hospital-administered chemotherapy given intravenously under oncology supervision, not a self-use peptide, and its risks require close clinical monitoring.

EMA-approved

Pegaspargase — Complete Research Guide (2026)

Last updated 2026-06-30

TL;DR

Pegaspargase is a peptide catalogued under Enzymes. Neutral reference entry; EU status: EU-approved prescription medicine.

What is Pegaspargase?

Pegaspargase (Oncaspar) is the pegylated, long-acting form of E. coli L-asparaginase, FDA-approved for acute lymphoblastic leukaemia and now a standard first-line asparaginase in modern ALL regimens.

Evidence is high-level and clinical, including a randomized phase 3 comparison against native asparaginase and a formal FDA first-line approval.

It is a regulator-approved oncology drug administered only under specialist supervision.

How does Pegaspargase work?

Like native asparaginase, pegaspargase depletes circulating L-asparagine, starving leukaemic lymphoblasts that cannot synthesise it and triggering their death.

Covalent attachment of polyethylene glycol (PEG) prolongs the enzyme's half-life and reduces immunogenicity, so a single dose sustains asparagine depletion for weeks instead of days.

What does the research say about Pegaspargase?

In the randomized DFCI 05-001 phase 3 trial, intravenous pegaspargase gave comparable asparaginase activity and outcomes to intramuscular native E. coli asparaginase with far fewer injections. ^[1]
Pharmacokinetic data show a single pegaspargase dose maintains asparaginase activity for roughly 2 to 3 weeks, versus the frequent dosing needed for native enzyme. ^[3]
Pegaspargase holds a formal FDA approval for first-line treatment of childhood ALL, reflecting its established place in standard regimens. ^[2]

Clinical research & studies

The references below are the primary sources cited throughout this guide. Each links directly to PubMed or the regulator. Where evidence is preclinical (animal or in-vitro), that is stated rather than implied.

[1] Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial — Place AE et al., The Lancet Oncology 2015. (Randomized open-label phase 3 trial)
[2] FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL) — Dinndorf PA et al., The Oncologist 2007. (Regulatory approval summary)
[3] Comparison of native E. coli and PEG asparaginase pharmacokinetics and pharmacodynamics in pediatric acute lymphoblastic leukemia — Panetta JC et al., Clinical Pharmacology and Therapeutics 2009. (Pharmacokinetic/pharmacodynamic study)
[4] Pegaspargase in Practice: Minimizing Toxicity, Maximizing Benefit — Riley DO et al., Current Hematologic Malignancy Reports 2021. (Clinical review)
[5] The association of age and adverse events of PEG-asparaginase in a pediatric tertiary care hospital; a retrospective review — Abbott L et al., European Journal of Haematology 2023. (Retrospective review)

Dosing context

This is not medical advice or a usage recommendation. Dosing figures are reported research context only, cited from the published literature.

Pegaspargase is given intravenously (or intramuscularly) as scheduled doses within paediatric and adult ALL protocols, with its long half-life allowing far fewer administrations than native asparaginase.

This is background context only; the treating oncology team determines dose, interval, and asparaginase-activity monitoring per protocol.

Side effects & safety profile

Pegaspargase shares the asparaginase toxicity class: hypersensitivity reactions, acute pancreatitis, thrombosis (including cerebral venous thrombosis), hepatotoxicity, hyperglycaemia, and hypertriglyceridaemia.

PEGylation lowers but does not eliminate immunogenicity, and silent inactivation with loss of asparaginase activity can still occur, warranting therapeutic activity monitoring.

Severe pancreatitis or anaphylaxis generally mandates permanent discontinuation.

Stacking & combinations

Pegaspargase is used only as one component of multi-agent ALL chemotherapy alongside vincristine, corticosteroids, anthracyclines, and antimetabolites.

Finding Pegaspargase vendors

This is an independent, neutral directory — we sell nothing and route no purchases. Use it to read regulatory context and (where available) genuine, moderated vendor information for your country.

Choose your country

We never list placeholder vendors. Pick your country to see neutral regulatory context.

Browse the directory

User reviews

No reviews yet

Reviews appear here once submitted and moderated. An aggregate rating is shown only after at least 5 genuine reviews — we never fabricate ratings.

Frequently asked questions

It is a long-acting, pegylated form of E. coli L-asparaginase used as chemotherapy for acute lymphoblastic leukaemia. The PEG coating makes it last much longer per dose than native asparaginase.

References

[1] Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial — Place AE et al., The Lancet Oncology 2015. PMID: 26549586. View sourceStudy: Randomized open-label phase 3 trialIV pegaspargase produced asparaginase activity and disease outcomes comparable to native IM asparaginase with fewer doses, supporting it as standard.
[2] FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL) — Dinndorf PA et al., The Oncologist 2007. PMID: 17766659. View sourceStudy: Regulatory approval summaryDocuments the FDA approval of pegaspargase for first-line paediatric ALL and the supporting efficacy and safety basis.
[3] Comparison of native E. coli and PEG asparaginase pharmacokinetics and pharmacodynamics in pediatric acute lymphoblastic leukemia — Panetta JC et al., Clinical Pharmacology and Therapeutics 2009. PMID: 19741605. View sourceStudy: Pharmacokinetic/pharmacodynamic studyPEG-asparaginase showed a substantially longer half-life and more prolonged asparagine depletion than native E. coli asparaginase.
[4] Pegaspargase in Practice: Minimizing Toxicity, Maximizing Benefit — Riley DO et al., Current Hematologic Malignancy Reports 2021. PMID: 33978914. View sourceStudy: Clinical reviewReviews practical management of pegaspargase toxicities (hypersensitivity, pancreatitis, thrombosis, hepatotoxicity) to keep patients on therapy.
[5] The association of age and adverse events of PEG-asparaginase in a pediatric tertiary care hospital; a retrospective review — Abbott L et al., European Journal of Haematology 2023. PMID: 36151599. View sourceStudy: Retrospective reviewReports the pattern and age-association of PEG-asparaginase adverse events in a paediatric ALL population.

This article is for educational and research purposes only. Peptides discussed here are not approved for human consumption by the FDA, EMA, or equivalent regulators outside of specific clinical contexts. Always consult a licensed medical professional before any therapeutic use.